ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Antiviral drugs >Nevirapine

Nevirapine

Nevirapine Suppliers list
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Email: info@dakenchem.com
Products Intro: Product Name:Nevirapine
CAS:129618-40-2
Purity:99% Package:100g,500g,1KG,10KG,100KG
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: CAS:129618-40-2
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: Mainchem Co., Ltd.
Tel: +86-0592-6210733
Email: sales@mainchem.com
Products Intro: Product Name:Nevirapine
CAS:129618-40-2
Company Name: Chemwill Asia Co.,Ltd.
Tel: 86-21-51086038
Email: chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com
Products Intro: CAS:129618-40-2
Purity:0.99 Package:5KG;1KG;25KG PRICE quotation Remarks:Factory stock, quality assurance, price concessions
Company Name: Hubei Jusheng Technology Co.,Ltd.
Tel: 86-188-71490254
Email: peter@hubeijusheng.com
Products Intro: Product Name:nevirapine
CAS:129618-40-2
Purity:99% Package:5KG;1KG Remarks:C15H14N4O

Lastest Price from Nevirapine manufacturers

  • Nevirapine
  • US $1000.00 / KG
  • 2019-04-01
  • CAS:129618-40-2
  • Min. Order: 25KG
  • Purity: 99%
  • Supply Ability: 10tons
  • Nevirapine
  • US $1.00 / G
  • 2018-08-28
  • CAS:129618-40-2
  • Min. Order: 100G
  • Purity: 99%
  • Supply Ability: 50000tons
Nevirapine Basic information
Product Name:Nevirapine
Synonyms:6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE, 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-;6H-Dipyrido[2,3-b:3',2'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-Methyl-;11-Cyclopropyl-4-Methyl-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6(11H)-one;11-cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one;11-cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one;AIDS005653;BI-RG-587 & CD4-IgG;D00435
CAS:129618-40-2
MF:C15H14N4O
MW:266.3
EINECS:603-345-0
Product Categories:Other APIs;Active Pharmaceutical Ingredients;API;Anti-virals;Inhibitors;Intermediates & Fine Chemicals;Non-nucleoside Reverse Transcriptase;Pharmaceuticals
Mol File:129618-40-2.mol
Nevirapine Structure
Nevirapine Chemical Properties
Melting point 247°C
Boiling point 409.5°C (rough estimate)
density 1.1300 (rough estimate)
refractive index 1.6200 (estimate)
Fp 9℃
storage temp. -20°C Freezer
solubility DMSO: ≥22mg/mL
form powder
pka2.8(at 25℃)
color white to tan
Merck 14,6490
CAS DataBase Reference129618-40-2(CAS DataBase Reference)
Safety Information
Hazard Codes Xi
Risk Statements 36/37/38
Safety Statements 26-36-37/39
RIDADR UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany 2
RTECS JM5562500
HS Code 29339900
Hazardous Substances Data129618-40-2(Hazardous Substances Data)
Nevirapine Usage And Synthesis
Chemical PropertiesCrystalline Solid
Usesamyloidosis therapy
UsesLabelled Nevirapine , a potent (IC50=84nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase. Antiviral.;Labeled Nevirapine, intended for use as an internal standard for the quantification of Nevirapine by GC- or LC-mass spectrometry.
UsesA potent (IC50=84nM) and selective non-nucleoside inhibitorf HIV-1 reverse transcriptase
DefinitionChEBI: A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse tr nscriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Brand nameViramune (Boehringer Ingelheim);Nevimune.
Acquired resistanceOne or more changes within the HIV reverse transcriptase at amino acid positions 100, 103, 106, 108, 181, 188 and 190 are associated with resistance. These point mutations have also been implicated, either alone or in combination, in HIV resistance to other non-nucleoside reverse transcriptase inhibitors.
General DescriptionNevirapine (Viramune) is more than 90% absorbed by theoral route and is widely distributed throughout the body. Itdistributes well into breast milk and crosses the placenta.Transplacental concentrations are about 50% those ofserum. The drug is extensively transformed by cytochromeP450 (CYP) to inactive hydroxylated metabolites; it mayundergo enterohepatic recycling.
Pharmaceutical ApplicationsA synthetic heterocyclic compound formulated for oral use as anhydrous compound or as the hemihydrate in a liquid oral suspension.
PharmacokineticsOral absorption: c. 93%
Cmax 200 mg twice daily: c. 5.74 mg/L
Cmin 200 mg twice daily: c. 2.88 mg/L
Plasma half-life: c. 36 h
Volume of distribution: c. 1.21 L/kg
Plasma protein binding: c. 60%
Absorption and distribution
Nevirapine is orally very well absorbed and widely distributed. CNS penetration is good and the semen:plasma ratio is in the range of 0.6–1. It is distributed into breast milk.
Metabolism and excretion
It is extensively metabolized by cytochrome P450 enzymes into a number of hydroxylated intermediates that are subsequently conjugated with glucuronide. Around 81% of the dose is excreted in urine (<5% as unchanged compound) and 10% in feces. There is no significant change in the pharmacokinetics in renal impairment. It is contraindicated in patients with severe hepatic impairment; caution should be exercised in patients with moderate hepatic dysfunction.
Clinical UseTreatment of HIV-1 infection in adults and children over 2 months old (in combination with other antiretroviral therapies)
Reduction of maternal transmission of HIV to the fetus (recommended only for use in HIV-infected treatment-naive women in labor who have had no prior HIV therapy)
Side effectsLife-threatening hepatic events, including fulminant hepatitis, have been observed in treatment-naive patients, generally within the first few weeks of treatment, but sometimes later. Approximately half the patients also develop skin rash, with or without fever or constitutional symptoms. Women with elevated CD4 counts (>250 cells/mm3) appear to be at highest risk. Men with pretreatment CD4 counts >400 cells/mm3 are also at increased risk. These risks exist in the absence of underlying hepatic abnormalities and, in some cases, hepatic injury continues to progress despite discontinuation of treatment. Treatment should stop, and not be restarted, in patients with clinical evidence of hepatitis. A starting dose of 200 mg per day, with escalation to full dose if no adverse reaction occurs, reduces the frequency of reaction. Single doses given to mothers or infants for prevention of perinatal HIV infection appear safe.
Tag:Nevirapine(129618-40-2) Related Product Information
3-Amino-2-chloro-4-methylpyridine 2-Amino-4-Methylpyridine,Nevirapine NEVIRAPINE HEMIHYDRATE (100 MG) NEVIRAPINE RELATED COMPOUND A (15 MG) (5,11-DIHYDRO-6H-11-ETHYL-4-METHYL-DIPYRIDO[3,2-B2',3'-E][1,4]DIAZEPIN-6-ONE) 4-(Hydroxymethyl)nevirapine NEVIRAPINE RELATED COMPOUND B (15 MG) (5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE) NEVIRAPINE (ANHYDROUS) 4,4-DIMETHOXY-2-BUTANONE[FOR NEVIRAPINE] NEVIRAPINE FOR PEAK IDENTIFICATION NEVIRAPINE RELATED COMPOUND A (15 MG) (5,11-DIHYDRO-6H-11 -ETHYL-4-METHYL-DIPYRIDO[3,2-B2',3'-E][1,4]DIAZEPIN-6-ONE) NEVIRAPINE-D3 NEVIRAPINE, [3H]- NEVIRAPINE-D5 2-Hydroxy Nevirapine AMPRENAVIR NETOBIMIN NELFINAVIR Nevirapine